Lucid Diagnostics Inc
NASDAQ:LUCD
Lucid Diagnostics Inc
Cost of Revenue
Lucid Diagnostics Inc
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
L
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
Cost of Revenue
-$6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Becton Dickinson and Co
NYSE:BDX
|
Cost of Revenue
-$11.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-11%
|
|
Boston Scientific Corp
NYSE:BSX
|
Cost of Revenue
-$4.5B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-7%
|
|
Stryker Corp
NYSE:SYK
|
Cost of Revenue
-$7.5B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-10%
|
|
Abbott Laboratories
NYSE:ABT
|
Cost of Revenue
-$18B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-7%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cost of Revenue
-$2.5B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-14%
|
See Also
What is Lucid Diagnostics Inc's Cost of Revenue?
Cost of Revenue
-6m
USD
Based on the financial report for Dec 31, 2023, Lucid Diagnostics Inc's Cost of Revenue amounts to -6m USD.
What is Lucid Diagnostics Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-66%
Over the last year, the Cost of Revenue growth was -66%.